Xyvent-M Kid Tablet is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg, formulated specifically for pediatric use to manage allergic conditions. Levocetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, thereby reducing symptoms associated with allergic rhinitis such as sneezing, nasal congestion, and rhinorrhea. Montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction and airway inflammation, making it effective in preventing and managing asthma symptoms and allergic rhinitis. The combined action of these agents provides comprehensive relief from allergic manifestations, including seasonal and perennial allergic rhinitis and mild to moderate asthma in children. Xyvent-M Kid Tablet is generally well tolerated, with a low incidence of sedation due to the non-sedating profile of Levocetirizine. It is recommended to be administered once daily, preferably in the evening, to optimize therapeutic outcomes. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision. This combination therapy offers an effective and convenient option for pediatric patients requiring dual-action treatment for allergic respiratory conditions.